Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Bone Neoplasms × ridaforolimus × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 9 Sarcoma 4 Recurrence 4 Neoplasm Metastasis 4 Breast Neoplasms 4 Lymphoma 3 Solid Tumors 2 Prostatic Neoplasms 2 Ovarian Neoplasms 2 Multiple Myeloma 2 Glioblastoma 2 Endometrial Neoplasms 2 Solid Tumor 1 Primary Myelofibrosis 1 Osteosarcoma 1 Myelodysplastic Syndromes 1 Liposarcoma 1 Leukemia 1 Leiomyosarcoma 1 Hematologic Neoplasms 1 Gliosarcoma 1 Glioma 1 Fallopian Tube Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Bone Neoplasms 1 Advanced Cancers 1

Interventions

Ibandronic Acid 8 Zoledronic Acid 3 Irinotecan 3 Temozolomide 2 Radiation 2 Doxorubicin 2 Denosumab 2 Cyclophosphamide 2 Cryotherapy 2 Cryosurgery 2 selinexor 1 robatumumab 1 ridaforolimus 1 radium Ra 223 dichloride 1 pegfilgrastim 1 palbociclib 1 liposomal doxorubicin 1 cc-486 1 anlotinib 1 Vincristine 1 Topotecan 1 Taxes 1 Radiotherapy 1 Pregabalin 1 Paclitaxel 1 Observation 1 Lomustine 1 Kyphoplasty 1 Injections 1 Ifosfamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00538239 2015-02-13

SUCCEED

Merck Sharp & Dohme LLC

Phase 3 Completed

Bone Neoplasms, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡